Sign up USA
Proactive Investors - Run By Investors For Investors

NetScientific brings in ex-Novartis man to deliver diagnostics portfolio

Diagnostics executive and ex- Novartis man Gene Walther has been appointed the head of NetScientific's (LON:NSCI) portfolio firm Vortex BioSciences - as the biomedical firm continues to restructure towards a sector franchise model.
NetScientific brings in ex-Novartis man to deliver diagnostics portfolio
Vortex BioSciences is developing a bench top instrument, which runs a simplified, high-speed blood test for a wide range of metastatic cancers

Diagnostics executive and ex- Novartis man Gene Walther has been appointed the head of NetScientific's (LON:NSCI) portfolio firm  Vortex BioSciences - as the biomedical firm continues to restructure towards a sector franchise model.

Walther also becomes head of the group's diagnostic franchise.

Vortex BioSciences is developing a bench top instrument, which runs a simplified, high-speed blood test for a wide range of metastatic cancers.

The firm is currently run by interim chief executive Dr Michael Boyce-Jacino who is leaving the group and board at the end of December this year.

NetScientific's group chief executive Francois Martelet said on Monday: "Gene's experience and calibre will further strengthen our team to help drive our commercialisation programme for Vortex and our entire diagnostics franchise, as part of our planned management restructure."

Walther will join on  January 4 to accelerate the development and delivery of Vortex's laboratory systems and spearhead the co-ordination and delivery of  its  diagnostics portfolio.

Among his previous roles, he served as the executive chairman of GenturaDx where he led this start-up diagnostics firm through product and company development leading to a strategic acquisition by Luminex.

He also spent 11 years at Novartis as president and global Head of diagnostics.

Walther said today: "Vortex has the potential to revolutionise the way cancer is diagnosed, monitored and treated. I'm excited to be able to play a role in the commercialisation of this technology."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

biotech2.jpg
Fri
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
"Cancer" in bold
July 27 2017
Undoubtedly the highlight was the successful completion of US and European studies evaluating over 400 patients using the company’s Parsortix system
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use